Halozyme Therapeutics Inc (HALO)

[biotech2020]

I have been adding over the last few months because I agree with the Wells Fargo report from last week, courtesy of dough?@tgtxdough on Twitter.
Strong ENHANZE Sales,PEGPH20 Catalyst Coming-see significant upside potential under any scenario into YE16:
We are maintaining our Outperform rating on shares of HALO following 2Q16 results and ahead of updated phase 2 data for PEGPH20 in pancreatic cancer. Strong performance on ENHANZE partner products HERCEPTIN SC and MABTHERA SC, provide increasing downside support for PEGPH20 and in fact, we would argue that without PEGPH20 spend HALO could be highly profitable with an attractive topline growth profile supporting upside from current levels. We do expect phase 2 data in 4Q16 to support phase 3 success with PEGPH20 and as such see significant upside potential under any scenario into YE16.